ストックスクリーナーアプリを入手
25.24
2.73%
0.67
アフターアワーズ：
25.19
-0.05
-0.20%
前日終値:
$24.57
開ける：
$24.66
24時間の取引高:
3.64M
Relative Volume:
3.44
時価総額：
$1.47B
収益：
$32.87M
当期純損益:
$674.31M
株価収益率:
2.2218
EPS:
11.36
ネットキャッシュフロー:
$-330.11M
1週間 パフォーマンス:
-42.18%
1か月 パフォーマンス:
-41.91%
6か月 パフォーマンス:
-16.17%
1年 パフォーマンス:
-54.56%
1日の値動き範囲:
$23.00
$25.94
1週間の範囲:
$22.24
$46.00
52週間の値動き範囲:
$22.24
$62.45
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
名前
Agios Pharmaceuticals Inc
セクター
電話
617-649-8600
住所
88 SIDNEY STREET, CAMBRIDGE, MA
AGIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
25.24 | 1.43B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-20 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | 開始されました | H.C. Wainwright | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-09-27 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-03 | 開始されました | Piper Sandler | Overweight |
| 2022-11-17 | アップグレード | Goldman | Sell → Neutral |
| 2022-07-27 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | 開始されました | BofA Securities | Buy |
| 2021-07-30 | ダウングレード | Goldman | Neutral → Sell |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-10 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-03-01 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-03-04 | 開始されました | Barclays | Equal Weight |
| 2019-11-26 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-02-15 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | 開始されました | Leerink Partners | Mkt Perform |
| 2018-05-23 | 開始されました | Citigroup | Buy |
| 2018-04-11 | 繰り返されました | Credit Suisse | Outperform |
| 2018-02-15 | 繰り返されました | Needham | Buy |
| 2018-02-15 | 繰り返されました | SunTrust | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-08-10 | 繰り返されました | Needham | Buy |
| 2017-08-08 | 繰り返されました | SunTrust | Buy |
| 2017-08-02 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | ダウングレード | Janney | Buy → Neutral |
| 2017-01-17 | アップグレード | Oppenheimer | Perform → Outperform |
| 2016-10-24 | 開始されました | Needham | Buy |
| 2016-06-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2016-05-18 | 繰り返されました | SunTrust | Buy |
すべてを表示
Agios Pharmaceuticals Inc (AGIO) 最新ニュース
Agios rebounds as Leerink upgrades to Outperform on selloff - MSN
Why Agios Plummeted, Losing Half Its Value, While Fulcrum Surged - MSN
AGIO: JP Morgan Lowers Price Target to $20.00 -- Maintains Neutral Rating | AGIO Stock News - GuruFocus
Agios Pharma stock price target lowered to $48 at H.C. Wainwright on mixed trial data - Investing.com Canada
Leerink Partners upgrades Agios Pharma stock on thalassemia potential By Investing.com - Investing.com Canada
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results - Yahoo Finance
How Recent Events Are Reshaping the Agios Pharmaceuticals Investment Story - Yahoo Finance
Agios slumps on mixed Phase III trial of mitapivat in sickle cell disease - The Pharma Letter
Agios stock rebounds as Leerink upgrades (AGIO:NASDAQ) - Seeking Alpha
Will Agios Pharmaceuticals Inc. (8AP) stock beat growth indexesStock Surge & Safe Capital Allocation Plans - newser.com
Agios Pharmaceuticals Stock Suffers Record Wipeout As Wall Street Warns Of 'Uncertain' Regulatory Path For Sickle Cell Drug - Stocktwits
Agios Pharma stock plunges on mixed Pyrukynd sickle cell trial results - Investing.com India
AGIO: Leerink Partners Upgrades Rating, Lowers Price Target | AG - GuruFocus
AGIO: Goldman Sachs Lowers Price Target, Maintains Neutral Ratin - GuruFocus
Leerink Partners upgrades Agios Pharma stock on thalassemia potential - Investing.com India
Agios Pharmaceuticals price target lowered to $25 from $40 at Goldman Sachs - TipRanks
Agios Pharmaceuticals (AGIO) Receives Upgrade Despite Mixed Tria - GuruFocus
Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
RBC Downgrades Agios Pharmaceuticals to Sector Perform From Outperform, Cuts Price Target to $28 From $57 - MarketScreener
Leerink Partners Upgrades Agios Pharmaceuticals to Outperform From Market Perform, PT is $34 - MarketScreener
AGIO: HC Wainwright Lowers Price Target But Maintains Buy Rating - GuruFocus
Published on: 2025-11-20 04:28:25 - newser.com
Published on: 2025-11-20 00:18:11 - newser.com
How Agios Pharmaceuticals Inc. (8AP) stock moves on employment dataJuly 2025 Market Mood & Precise Entry and Exit Recommendations - newser.com
Published on: 2025-11-19 21:36:35 - newser.com
Will Agios Pharmaceuticals Inc. (8AP) stock hit analyst forecasts - newser.com
How Agios Pharmaceuticals Inc. (8AP) stock correlates with oil marketsOil Prices & Fast Entry and Exit Trade Plans - newser.com
Published on: 2025-11-19 18:19:52 - newser.com
Agios Pharma stock price target cut to $32 from $54 at BofA on SCD trial results By Investing.com - Investing.com South Africa
Agios Makes Case For Pyrukynd Approval In SCD Despite Mixed Phase III Results - Citeline News & Insights
Will Agios Pharmaceuticals Inc. stock see PE expansionProduct Launch & High Return Trade Opportunity Guides - newser.com
Agios Pharmaceuticals Plunges Over 50% as Sickle Cell Drug Delivers Mixed Phase 3 Results - FinancialContent
Agios planning sNDA on mixed sickle cell data for mitapivat - BioWorld MedTech
This Biotech Just Lost Half Its Value As Its Rival Celebrated - Investor's Business Daily
Agios reports mixed results in sickle cell disease trial of mitapivat - Investing.com Nigeria
Agios Pharma: Study Fail May Affect Mitapivat TDT ApprovalExpect More Volatility (AGIO) - Seeking Alpha
Agios Pharma stock price target cut to $32 from $54 at BofA on SCD trial results - Investing.com UK
Agios Shares Plunge 50% After Mixed Phase 3 RISE UP Results For Mitapivat - Nasdaq
Why Shares in Agios Pharmaceuticals Got Crushed Today - AOL.com
Agios Pharmaceuticals (AGIO) Faces Downgrade Amid Sickle Cell Drug Data - GuruFocus
Agios Pharma stock rating downgraded by RBC Capital after mixed trial data - Investing.com
Why Shares in Agios Pharmaceuticals Got Crushed Today - The Motley Fool
RBC downgrades Agios to Sector Perform after mitapivat ‘falls short’ - TipRanks
Agios Pharmaceuticals (AGIO) Faces Uncertainty After Trial Resul - GuruFocus
Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results - Benzinga
Agios Pharmaceuticals (AGIO) Sees Sharp Decline in Stock Price - GuruFocus
Agios shares fall on mixed sickle cell results for blood disease drug - BioPharma Dive
Why Is Agios Pharmaceuticals Stock Sinking Today? - Benzinga
Agios shares tumble on mixed results for sickle cell drug trial - MSN
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Agios hit as mitapivat delivers mixed data in pivotal sickle cell study - FirstWord Pharma
Agios Pharmaceuticals Inc (AGIO) 財務データ
収益
当期純利益
現金流量
EPS
1.38%
1.42%
大文字化:
|
ボリューム (24 時間):